Alnylam Pharmaceuticals: Positive New Results of Lumasiran in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (ALNY) led the translation of RNA interference (RNAi) into a new class of innovative therapeutics, transforming the lives of people afflicted with rare and prevalent diseases with unmet needs.

RNAi is a natural cellular process of gene silencing that represents  promising and rapidly advancing frontiers in biology and drug . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.